Sean A Yamada-Hunter, Johanna Theruvath, Brianna J McIntosh, Katherine A Freitas, Frank Lin, Molly T Radosevich, Amaury Leruste, Shaurya Dhingra, Naiara Martinez-Velez, Peng Xu, Jing Huang, Alberto Delaidelli, Moksha H Desai, Zinaida Good, Roel Polak, Audre May, Louai Labanieh, Jeremy Bjelajac, Tara Murty, Zach Ehlinger, Christopher W Mount, Yiyun Chen, Sabine Heitzeneder, Kristopher D Marjon, Allison Banuelos, Omair Khan, Savannah L Wasserman, Jay Y Spiegel, Sebastian Fernandez-Pol, Calvin J Kuo, Poul H Sorensen, Michelle Monje, Robbie G Majzner, Irving L Weissman, Bita Sahaf, Elena Sotillo, Jennifer R Cochran, Crystal L Mackall
Adoptively transferred T cells and agents designed to block the CD47-SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system1,2 . Here we administered anti-CD47 antibodies in combination with adoptively transferred T cells with the goal of enhancing antitumour efficacy but observed abrogated therapeutic benefit due to rapid macrophage-mediated clearance of T cells expressing chimeric antigen receptors (CARs) or engineered T cell receptors. Anti-CD47-antibody-mediated CAR T cell clearance was potent and rapid enough to serve as an effective safety switch...
May 15, 2024: Nature